Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Feeds
4445 items (4445 unread) in 80 feeds
Acinar Cell Carcinoma
(28 unread)
Acinic Cell Carcinoma
(32 unread)
Adenoid Cystic Carcinoma
(54 unread)
Adrenal Gland Cancer
(324 unread)
Ampulla Of Vater
(13 unread)
Anal Cancer
(250 unread)
Angiosarcoma
(72 unread)
Appendix Cancer
(34 unread)
Bile Duct Cancer
(382 unread)
Brain and CNS
(1106 unread)
Carcinoid
(141 unread)
Endocrine/Neuroendocrine
(272 unread)
Gall Bladder Cancer
(219 unread)
Hemangioendothelioma
(23 unread)
Hepatoblastoma
(30 unread)
Pancreas
(45 unread)
Phyllodes
(18 unread)
PMP and Mucinous Tumors
(16 unread)
Rhabdomyosarcoma
(180 unread)
Sarcoma
(545 unread)
Twitter Pals
(661 unread)
Trial - Brain Tumor (2 unread)
-
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
Posted: May 11th, 2010, 8:00am MDT
-
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Posted: May 7th, 2010, 8:00am MDT
Conditions: Acoustic Schwannoma; Adult Anaplastic Meningioma; Adult Ependymoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Meningeal Hemangiopericytoma; Adult Papillary Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012